Enlivex Secures FDA RMAT Designation for Allocetra in Knee Osteoarthritis
Phase IIb trial now underway with first U.S. patient dosed.
/ 220 items
#andre↓
TNXP Stock Rises on Expanded Medicare Access for Fibromyalgia Drug TONMYA
Tonix secured expanded Medicare coverage for its fibromyalgia drug TONMYA, reaching approximately 9 million additional patients starting January 2027.
Bempikibart Delivers Promising Hair Regrowth in Alopecia Trial, Sending Q32 Bio Stock Soaring
The experimental treatment showed meaningful hair regrowth and a favorable safety profile.
Goldman Sachs Initiates Coverage on Stoke Therapeutics with Buy Rating and $44 Price Target
The firm sees strong potential for zorevunersen in treating Dravet syndrome.
First New Essential Tremor Therapy in 50+ Years: Goldman Bullish on Praxis Precision
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
Analyst Upgrade Boosts BeOne Medicines as Brukinsa Outlook Strengthens
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.